Literature DB >> 17318019

Relationship of sodium/iodide symporter expression with I131 whole body scan uptake between primary and metastatic lymph node papillary thyroid carcinomas.

S J Lee1, K-C Choi, J P Han, Y-E Park, M G Choi.   

Abstract

The aim of the present study was to evaluate total and membranous Na+/I- symporter (NIS) expressions in papillary thyroid carcinoma (PTC) tissue, correlation of NIS expression between primary and metastatic lymph node (LN) PTC tissues, and relationship of NIS expression with I131 whole body scan (WBS) uptake between primary and metastatic LN PTC tissues by analyzing 17 pairs of primary and metastatic LN PTC tissues. Staining positivity was calculated, and staining intensity was graded as negative (0), weak (1+), moderate (2+) and strong (3+). In primary PTC tissues, positivities and intensities of normal cells were higher than those of carcinoma cells but had no correlation with those in matched metastatic LN PTC tissues. In classic type, positivities, intensities and membranous intensities (mIS) were correlated between primary and matched metastatic LN PTC tissues. In patients aged younger than 45 yr, positivities and intensities in primary PTC tissues had correlation with those in matched metastatic LN PTC tissues. Positivities, intensities, mIS and pathological subtype of carcinoma cells in primary PTC tissues were not correlated with age, tumor size, TNM stage, MACIS score and thyroglobulin (Tg) levels at the time of I131 WBS. Sensitivity, specificity, as well as positive and negative predicted values of mIS in patients with I131 WBS uptake were 69.2, 75, 90 and 42.9% in primary PTC tissues, and 92.3, 100, 100 and 80% in metastatic LN PTC tissues. The results of mIS taken either as positive or negative were correlated with those of I131 WBS after controlling for age. Our results demonstrate that PTC tissues have altered total and membranous NIS expressions, suggesting that NIS expression in primary PTC tissues may predict NIS expression and I131 WBS uptake in matched metastatic LN PTC tissues.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17318019     DOI: 10.1007/bf03347392

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  32 in total

Review 1.  Thyroid iodine transport.

Authors:  C Spitzweg; A E Heufelder; J C Morris
Journal:  Thyroid       Date:  2000-04       Impact factor: 6.568

Review 2.  Implications of the molecular characterization of the sodium-iodide symporter (NIS).

Authors:  C Schmutzler; J Köhrle
Journal:  Exp Clin Endocrinol Diabetes       Date:  1998       Impact factor: 2.949

3.  The WHO histological classification of thyroid tumors: a commentary on the second edition.

Authors:  C Hedinger; E D Williams; L H Sobin
Journal:  Cancer       Date:  1989-03-01       Impact factor: 6.860

4.  Na(+)-I- symport activity is present in membrane vesicles from thyrotropin-deprived non-I(-)-transporting cultured thyroid cells.

Authors:  S M Kaminsky; O Levy; C Salvador; G Dai; N Carrasco
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

Review 5.  Iodide transport in the thyroid gland.

Authors:  N Carrasco
Journal:  Biochim Biophys Acta       Date:  1993-06-08

6.  Post-transcriptional regulation of the sodium/iodide symporter by thyrotropin.

Authors:  C Riedel; O Levy; N Carrasco
Journal:  J Biol Chem       Date:  2001-04-04       Impact factor: 5.157

7.  Rapid communication: predominant intracellular overexpression of the Na(+)/I(-) symporter (NIS) in a large sampling of thyroid cancer cases.

Authors:  O Dohán; Z Baloch; Z Bánrévi; V Livolsi; N Carrasco
Journal:  J Clin Endocrinol Metab       Date:  2001-06       Impact factor: 5.958

8.  Relationship between expression of the sodium/iodide symporter and 131I uptake in recurrent lesions of differentiated thyroid carcinoma.

Authors:  J J Min; J K Chung; Y J Lee; J M Jeong; D S Lee; J J Jang; M C Lee; B Y Cho
Journal:  Eur J Nucl Med       Date:  2001-05

9.  Expression of the Na+/I- symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes.

Authors:  V Lazar; J M Bidart; B Caillou; C Mahé; L Lacroix; S Filetti; M Schlumberger
Journal:  J Clin Endocrinol Metab       Date:  1999-09       Impact factor: 5.958

10.  Na+/I- symporter distribution in human thyroid tissues: an immunohistochemical study.

Authors:  B Caillou; F Troalen; E Baudin; M Talbot; S Filetti; M Schlumberger; J M Bidart
Journal:  J Clin Endocrinol Metab       Date:  1998-11       Impact factor: 5.958

View more
  5 in total

1.  Sorafenib treatment of radioiodine-refractory advanced thyroid cancer in daily clinical practice: a cohort study from a single center.

Authors:  Marco Gallo; Federica Michelon; Anna Castiglione; Francesco Felicetti; Alessandro Adriano Viansone; Alice Nervo; Clizia Zichi; Giovannino Ciccone; Alessandro Piovesan; Emanuela Arvat
Journal:  Endocrine       Date:  2014-11-21       Impact factor: 3.633

2.  Seaweed and Iodine Intakes and SLC5A5 rs77277498 in Relation to Thyroid Cancer.

Authors:  Tung Hoang; Eun Kyung Lee; Jeonghee Lee; Yul Hwangbo; Jeongseon Kim
Journal:  Endocrinol Metab (Seoul)       Date:  2022-05-24

Review 3.  Visualization of gene expression in the live subject using the Na/I symporter as a reporter gene: applications in biotherapy.

Authors:  Patrick Baril; Pilar Martin-Duque; Georges Vassaux
Journal:  Br J Pharmacol       Date:  2009-10-08       Impact factor: 8.739

4.  NIS expression in thyroid tumors, relation with prognosis clinicopathological and molecular features.

Authors:  Catarina Tavares; Maria João Coelho; Catarina Eloy; Miguel Melo; Adriana Gaspar da Rocha; Ana Pestana; Rui Batista; Luciana Bueno Ferreira; Elisabete Rios; Samia Selmi-Ruby; Bruno Cavadas; Luísa Pereira; Manuel Sobrinho Simões; Paula Soares
Journal:  Endocr Connect       Date:  2018-01       Impact factor: 3.335

5.  A novel microfluidic device capable of maintaining functional thyroid carcinoma specimens ex vivo provides a new drug screening platform.

Authors:  Andrew Riley; Victoria Green; Ramsah Cheah; Gordon McKenzie; Laszlo Karsai; James England; John Greenman
Journal:  BMC Cancer       Date:  2019-03-22       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.